Coiled Therapeutics (LSE:COIL), one of the newer biotechnology names on London's AIM market, has reported steady clinical progress during 2026 as it develops its experimental cancer drug AO-252. The company has completed patient enrolment in two dose cohorts, developed an improved formulation of the drug and set out a target of treating 30 patients by the end of 2026. Following its interim results for the six months to 30 June 2026, management has said it hopes to report first data from the new formulation by the end of the year.
What the Company Does
Coiled Therapeutics is a clinical-stage drug developer focused on oncology. Its lead asset, AO-252, is an experimental cancer therapy being tested in an early-stage clinical trial. The company was created through a transaction involving Roquefort Therapeutics, which had been listed on London's Main Market. According to legal adviser Fieldfisher, the deal comprised a £31.9 million acquisition, a share raise and admission to AIM, and other reports said the company raised £10.8 million as it moved from the Main Market to AIM.
Latest Developments
In March 2026, Coiled completed its transition to a clinical-stage company. Later announcements focused on AO-252's development. The company developed an improved formulation of the drug ahead of an expansion of its trial, and subsequently filled two dose cohorts as the reworked therapy advanced.
A summary of a company announcement stated that Coiled had completed enrolment in two AO-252 dose cohorts and was aiming to reach 30 patients by the end of 2026. A further report said the company expected first data from the new formulation by the year end. A share issue was announced in May 2026, and Coiled has also said it would participate in the Small Cap Showcase investor event.
Financial Picture
Coiled published interim results to 30 June 2026, though detailed figures were not available at the time of writing. As a clinical-stage biotech without product sales, the company's accounts are likely to reflect R&D spending and administrative costs, funded by Share Capital raised around its AIM admission and subsequent share issues. No Dividend is paid, and the company's cash runway relative to its trial plans will be a key consideration for shareholders.
Sector and index Context
Coiled is a member of the FTSE AIM All Share Index, which includes many small life sciences companies seeking to advance early-stage assets. Oncology remains one of the most active areas of Drug Development worldwide, with large pharmaceutical groups regularly licensing or acquiring promising early-stage programmes. However, funding conditions for small biotechs on AIM have been challenging, and investors tend to look for clear clinical milestones before committing new capital.
Key Risks
Early-stage drug development carries a high risk of failure. AO-252 could encounter safety issues, lack of efficacy or delays in patient recruitment. Changes in formulation may also introduce uncertainty, as new versions of a drug need to show suitable performance in patients. Coiled is likely to require additional funding to progress through later trial phases, which could dilute existing shareholders. As with many small AIM biotechs, the shares may be volatile around news flow.
What to Watch Next
The key near-term milestone is the release of first data from the new AO-252 formulation, which the company has indicated it expects by the end of 2026. Investors will also follow progress towards the 30-patient enrolment target, any update on the next stage of the clinical programme and the company's funding position. Partnering discussions or licensing interest would be further signals of external validation for the asset.






Please wait processing your request...